The UK Medicines and Healthcare products Regulatory Agency (MHRA) has clarified its approach to determining whether a product qualifies as a medicinal product, a critical consideration for pharmaceutical companies navigating compliance. This guidance addresses the complexities surrounding borderline products, which may straddle the line between medicines and other categories, such as cosmetics or dietary supplements. The MHRA’s criteria focus on the intended purpose of the product, its claims, and the mode of action, which are essential for regulatory classification.
In the current landscape, where innovation often leads to novel product formulations, understanding these distinctions is vital for companies involved in regulatory affairs, quality assurance, and product development. Misclassifying a product can lead to significant legal and financial repercussions, making it imperative for stakeholders to stay informed about the MHRA’s evolving guidelines. As the regulatory environment continues to adapt, maintaining clarity on what constitutes a medicinal product will be essential for ensuring compliance and safeguarding market access.
Get started today with Solo access →
